Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
Stopped early · Phase 2
Conditions studied: Breast Cancer
In brief
RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment. PURPOSE: This clinical trial is studying how well genetic testing works in predicting response to paclitaxel in women who have unresected breast cancer.
Key facts
- Study ID
- NCT00088829
- Run by
- Georgetown University
- People needed
- 22
- Starts
- 2001-04-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2018-07-11
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
Where it is running
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center — Washington D.C., District of Columbia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.